|   In the News

CAR-T growing up with big pharma’s big bet

BioPharmaDIVE: In the span of just five months, Gilead Sciences Inc. and Celgene Corp. — both large-cap biotechs with long-term growth worries — each made major bets on the potential of cancer cell therapies. With two of the three largest biotech deals in the last 12 months, Gilead’s purchase of Kite Pharma and Celgene’s buy of Juno Therapeutics injected a combined $20 billion into the emerging field.

Read more.


  |   News

Targeted protein degraders are redefining how small molecules look and act

When the first human genome was sequenced, researchers finally got a glimpse of the true dimensions of our proteome—the tens of thousands of proteins responsible for sickness and health. Ever since, scientists have explored the morass for drivers of diseases, generating a long wish list of proteins they’d like to control.

Read more.


  |   In the News

Investors are making bigger first-time bets — not more bets — on life sciences companies

For an early-stage biotech company, raising venture capital funding for the first time is a crucial milestone. And when you look at all the baby’s-first-financing announcements of the past few years, there’s something going on that Atlas Venture VC Bruce Booth calls “so counterintuitive in a lot of ways.”

Read more.


  |   From the Trenches

Two’s Company, Three’s Diversity

Two years ago, Bloomberg Business published a feature entitled At Biotech Party, Gender Diversity Means Cocktail Waitresses. Within three weeks of publication, more than 200 individuals had signed a letter urging the biotech industry to stop hiring models at business cocktail parties. I appreciate that signing this letter wasn’t a direct commitment to improve gender diversity. But I thought it would be an interesting exercise to assess each of the signatories’ companies against a higher gender diversity metric to see if this talk translated into action.

This blog was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   LifeSciVC

Bringing The Human Element Full Circle Thru Adaptive Ski Coaching

By Bruce Booth, DPhil, Partner

My experience as an adaptive ski coach has been nothing short of life-changing. I don’t say that with hyperbole. By bringing together my passion for the mountains with my profession as an investor in biomedical therapies, adaptive coaching completes the circle for me – by focusing on the most important of life’s elements: the human element.

Read more.